Salinomycin suppresses TGF-β1-induced EMT by down-regulating MMP-2 and MMP-9 via the AMPK/SIRT1 pathway in non-small cell lung cancer

Salinomycin (Sal) is a recently identified anti-tumor drug for treating several types of solid tumor; however, its effects on the migratory and invasive properties of non-small cell lung cancer (NSCLC) remain unclear. This study investigated the inhibitory effect underlying mechanisms of Salon transforming growth factor-beta 1 (TGF-beta 1)-induced epithelial-to-mesenchymal transition (EMT) and cell migration. Sal solidly blocked cell migration and invasion enhancement by TGF-beta 1-induced EMT, through recovering E-cadherin loss and suppressing mesenchymal markers induction, as well as TGF-beta 1-mediated AMPK/SIRT signaling activity upregulation. The pharmacologic inhibition or knockdown of AMPK or SIRT1 can act synergistically with Sal to inhibit TGF-beta 1-induced MMP-2 and MMP-9. In contrast, AMPK or SIRT1 upregulation can protect against TGF-beta 1-induced MMP-2 and MMP-9 inhibition by Sal. Next we demonstrated that the MMP-2 and MMP-9 knockdown can act synergistically with Sal to inhibit TGF-beta 1-induced EMT. Moreover, treatment of PMA of MMP activator increased TGF-beta 1-induced MMP-2 and MMP-9, even with Sal. Our results demonstrate that Sal suppresses TGF-beta 1-induced EMT by downregulating MMP-2 and MMP-9 through the AMPK/SIRT pathway, thereby inhibiting lung cancer cell migration and invasion.

Automated summary

Salinomycin (Sal) inhibits TGF-beta 1-induced EMT by downregulating MMP-2 and MMP-9 through the AMPK/SIRT pathway, thereby blocking lung cancer cell migration and invasion.